CalciMedica (NASDAQ:CALC) Issues Quarterly Earnings Results, Misses Estimates By $0.12 EPS

CalciMedica (NASDAQ:CALC) released its quarterly earnings data on Tuesday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.12), Zacks reports.

CalciMedica Trading Up 1.4%

Shares of CalciMedica stock traded up $0.01 on Tuesday, hitting $0.67. 48,022 shares of the company traded hands, compared to its average volume of 1,074,619. The company has a market cap of $10.55 million, a PE ratio of -0.51 and a beta of 0.91. The stock’s 50 day moving average price is $0.83 and its 200-day moving average price is $0.88. CalciMedica has a 52 week low of $0.46 and a 52 week high of $7.20.

Analysts Set New Price Targets

Several brokerages recently issued reports on CALC. HC Wainwright restated a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $10.00.

Insider Transactions at CalciMedica

In other news, Director Fred A. Middleton acquired 248,972 shares of CalciMedica stock in a transaction on Thursday, June 25th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $199,177.60. Following the acquisition, the director directly owned 1,063,272 shares of the company’s stock, valued at $850,617.60. This trade represents a 30.57% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 28.25% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CalciMedica

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Envestnet Asset Management Inc. lifted its holdings in CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after buying an additional 34,386 shares during the period. Renaissance Technologies LLC lifted its position in CalciMedica by 26.1% during the fourth quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after purchasing an additional 18,300 shares during the period. Boothbay Fund Management LLC purchased a new stake in CalciMedica in the fourth quarter valued at $506,000. Cetera Investment Advisers grew its position in CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after purchasing an additional 9,045 shares during the period. Finally, Jane Street Group LLC purchased a new position in shares of CalciMedica during the 4th quarter valued at about $127,000.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.